Internal Medicine · Fremont, CA
NPI
1629180310
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
0
Medicare group memberships
Hospitals
3
Hospital affiliations
734 Mowry Ave
Fremont, CA, 94536
Phone (510) 742-6274
Medicare paid, 2024
$606K
8,611 services
Medicare patients, 2024
526
Average age 77
Drug cost, 2024
$3.3M
22,645 prescriptions
Company payments, 2025
$2,802
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rabin Khetrapal was code 99309 (snf e&m), 3,263 times for 301 patients. In total Rabin Khetrapal billed 8,611 services in 37 codes, and Medicare paid $606K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-01-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99309 SNF E&M | Facility | 3,263 | 301 | $94.61 | $309K |
| J0897 Injection, denosumab, 1 mg | Office | 2,820 | 32 | $20.00 | $56K |
| 99214 Office E&M - Established | Office | 770 | 181 | $118.99 | $92K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 288 | 134 | $14.94 | $4,303 |
| 99215 Office E&M - Established | Office | 202 | 118 | $165.71 | $33K |
| 99306 SNF E&M | Facility | 177 | 138 | $161.92 | $29K |
| 99497 Care Management/Coordination | Facility | 136 | 133 | $64.36 | $8,753 |
| 93000 Electrocardiogram | Facility | 96 | 75 | $11.51 | $1,104 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Facility | 92 | 92 | $141.29 | $13K |
| 96372 Injection Administration | Office | 69 | 38 | $13.26 | $915 |
| 99497 Care Management/Coordination | Office | 62 | 57 | $74.84 | $4,640 |
| G0008 Administration of influenza virus vaccine | Office | 59 | 56 | $38.68 | $2,282 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 58 | 58 | $157.34 | $9,125 |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 56 | 47 | $50.21 | $2,812 |
| 93000 Electrocardiogram | Office | 53 | 49 | $12.73 | $675 |
By year: 2022 $543K for 10,473 services; 2023 $509K for 7,831 services; 2024 $606K for 8,611 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rabin Khetrapal prescribed most often to Medicare patients was Atorvastatin Calcium, with 1,499 prescriptions and refills. In total Rabin Khetrapal wrote 22,645 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 1,499 | 1,990 | 217 | $25K |
| Levothyroxine Sodium Generic | 959 | 1,133 | 112 | $14K |
| Pantoprazole Sodium Generic | 650 | 836 | 115 | $25K |
| Amlodipine Besylate Generic | 584 | 784 | 106 | $6,881 |
| Farxiga Dapagliflozin Propanediol | 578 | 630 | 55 | $222K |
| Furosemide Generic | 554 | 608 | 89 | $4,954 |
| Metformin Hcl Generic | 549 | 683 | 84 | $9,305 |
| Valsartan Generic | 525 | 691 | 80 | $19K |
| Eliquis Apixaban | 446 | 474 | 48 | $173K |
| Metoprolol Succinate Generic | 423 | 590 | 69 | $11K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 386 | 387 | 22 | $38K |
| Trulicity Dulaglutide | 371 | 389 | 23 | $194K |
| Tamsulosin Hcl Generic | 351 | 391 | 51 | $9,197 |
| Gabapentin Generic | 316 | 379 | 56 | $7,346 |
| Lisinopril Generic | 311 | 379 | 44 | $4,645 |
Brand drugs: 5,603 claims; generic drugs: 16,899 claims; opioid claims: 221.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rabin Khetrapal $2,802 ($2,802 in general payments such as food, travel and fees) from 27 companies. The largest payer was ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) with $274.
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 10 | $274 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 9 | $202 |
| Amgen Inc. AMGN | 7 | $194 |
| Janssen Pharmaceuticals, Inc JNJ | 8 | $190 |
| Novo Nordisk Inc NVO | 7 | $178 |
| Lundbeck LLC | 6 | $177 |
| Teva Pharmaceuticals USA, Inc. TEVA | 4 | $170 |
| Lilly USA, LLC LLY | 8 | $167 |
| Procept Biorobotics Corporation PRCT | 1 | $149 |
| Vanda Pharmaceuticals Inc. VNDA | 5 | $141 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.